Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil.
This study was designed to investigate the in vitro effects of phenolic compounds extracted from olive oil and from olive derived fractions. More specifically, we investigated the effects on platelets of 2-(3,4-di-hydroxyphenyl)-ethanol (DHPE), a phenol component of extra-virgin olive oil with potent antioxidant properties. The following variables were studied: aggregation of platelet rich plasma (PRP) induced by ADP or collagen, and thromboxane B2 production by collagen or thrombin-stimulated PRP. In addition, thromboxane B2 and 12-hydroxyeicosatetraenoic acid (12-HETE) produced during blood clotting were measured in serum. Preincubation of PRP with DHPE for at least 10 min resulted in maximal inhibition of the various measured variables. The IC50s (concentration resulting in 50% inhibition) of DHPE for ADP or collagen-induced PRP aggregations were 23 and 67 microM, respectively. At 400 microM DHPE, a concentration which completely inhibited collagen-induced PRP aggregation, TxB2 production by collagen- or thrombin-stimulated PRP was inhibited by over 80 percent. At the same DHPE concentration, the accumulation of TxB2 and 12-HETE in serum was reduced by over 90 and 50 percent, respectively. We also tested the effects of PRP aggregation of oleuropein, another typical olive oil phenol, and of selected flavnoids (luteolin, apigenin, quercetin) and found them to be much less active. On the other hand a partially characterized phenol-enriched extract obtained from aqueous waste from olive oil showed rather potent activities. Our results are the first evidence that components of the phenolic fraction of olive oil can inhibit platelet function and eicosanoid formation in vitro, and that other, partially characterized, olive derivatives share these biological activities.
D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000975:Antioxidants / Q000302:isolation & purification / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D015777:Eicosanoids / Q000096:biosynthesis*; D005419:Flavonoids / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis / Q000097:blood; D057888:Iridoid Glucosides; D039823:Iridoids; D000069463:Olive Oil; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000494:pharmacology; D010936:Plant Extracts / Q000737:chemistry; D010938:Plant Oils / Q000737:chemistry*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D011714:Pyrans / Q000302:isolation & purification / Q000494:pharmacology; D013929:Thromboxane B2 / Q000096:biosynthesis / Q000097:blood
D000975:Antioxidants; D015777:Eicosanoids; D005419:Flavonoids; D006893:Hydroxyeicosatetraenoic Acids; D057888:Iridoid Glucosides; D039823:Iridoids; D000069463:Olive Oil; D010936:Plant Extracts; D010938:Plant Oils; D010975:Platelet Aggregation Inhibitors; D011714:Pyrans; C005975:3,4-dihydroxyphenylethanol; C002769:oleuropein; D013929:Thromboxane B2; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000244:Adenosine Diphosphate; D003094:Collagen; D010626:Phenylethyl Alcohol